National Cancer Institute; Notice of Meeting, 4486-4487 [2019-02472]
Download as PDF
4486
Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices
Contact Person: Alexander D. Politis,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3210,
MSC 7808, Bethesda, MD 20892, (301) 435–
1150, politisa@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neurodevelopment, Signaling and
Circuitry.
Date: March 21, 2019.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Afia Sultana, Ph.D.
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Room 4189, Bethesda, MD
20892, (301) 827–7083, sultanaa@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Neuroscience Assay, Diagnostics
and Animal Model Development.
Date: March 22, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Westin Georgetown, Washington,
DC, 2350 M Street NW, Washington, DC
20037.
Contact Person: Susan Gillmor, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 240–762–3076, susan.gillmor@nih.gov
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, linical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 9, 2019.
Sylvia L. Neal,
Program Officer, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02403 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKBBV9HB2PROD with NOTICES
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
VerDate Sep<11>2014
19:41 Feb 14, 2019
Jkt 247001
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Molecular Atlas of Lung Development
Program (LungMAP).
Date: April 3, 2019.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7185, Bethesda, MD
20892, 301–827–7953, kristen.page@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Conference Grants in Support of Heart, Lung
and Blood Research.
Date: April 4–5, 2019.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Stephanie J. Webb, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7196,
Bethesda, MD 20892, 301–435–0291,
stephanie.webb@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI TOPMed: Omics Phenotypes of Heart,
Lung, and Blood Disorders (X01).
Date: April 5, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda One
Bethesda Metro Center Bethesda, MD 20814.
Contact Person: Susan Wohler Sunnarborg,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National, Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7182, Bethesda, MD 20892,
susan.sunnarborg@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Loan Repayment Program Review.
Date: April 9–11, 2019.
Time: April 09, 2019, 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Time: April 10, 2019, 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Time: April 11, 2019, 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Stephanie J. Webb, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7196,
Bethesda, MD 20892, 301–827–7992,
stephanie.webb@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Early Phase Clinical Trials (R61/R33).
Date: April 10, 2019.
Time: 1:00 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892, 301–827–7913, creazzotl@
mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Early Phase Clinical Trials (R33).
Date: April 10, 2019.
Time: 12:30 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Tony L. Creazzo, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7180, Bethesda, MD
20892, 301–827–7913, creazzotl@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: February 11, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02411 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Clinical Trials
and Translational Research Advisory
Committee.
E:\FR\FM\15FEN1.SGM
15FEN1
Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices
khammond on DSKBBV9HB2PROD with NOTICES
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will also be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov/).
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: July 17, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical and Translational Research
Programs.
Place: National Cancer Institute Shady
Grove, East Wing, Seminar Room 110, 9609
Medical Center Drive, Rockville, MD 20850.
Contact Person: Sheila A. Prindiville, MD,
MPH Director, Coordinating Center for
Clinical Trials, National Institutes of Health,
National Cancer Institute, Coordinating
Center for Clinical Trials, 9609 Medical
Center Drive, Room 6W136, Rockville, MD
20850, 240–276–6173 prindivs@mail.nih.gov.
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: November 6, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical and Translational Research
Programs.
Place: National Cancer Institute Shady
Grove, East Wing, Conference, Room TE406,
9609 Medical Center Drive, Rockville, MD
20850.
Contact Person: Sheila A. Prindiville, MD,
MPH, Director, Coordinating Center for
Clinical Trials, National Institutes of Health,
National Cancer Institute, Coordinating
Center for Clinical Trials, 9609 Medical
Center Drive, Room 6W136, Rockville, MD
20850, 240–276–6173, prindivs@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NCI Shady Grove
has instituted stringent procedures for
entrance into the NCI Shady Grove building.
Visitors will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
VerDate Sep<11>2014
19:41 Feb 14, 2019
Jkt 247001
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 11, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02472 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Council of Research Advocates.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov).
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: April 11, 2019.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: Welcome and Chairman’s
Remarks, NCI Updates, Legislative Update,
Budget Update, and Director’s Update.
Place: National Institutes of Health, 31
Center Drive, Building 31, 11A01, Bethesda,
MD 20892.
Contact Person: Amy Williams, NCI Office
of Advocacy Relations, National Cancer
Institute, NIH, 31 Center Drive Building 31,
Room 10A28, Bethesda, MD 20892, 240–781–
3360, williaam@mail.nih.gov.
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: June 05, 2019.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: Welcome and Chairman’s
Remarks, NCI Updates, Legislative Update,
Budget Update, and Director’s Update.
Place: National Institutes of Health 31
Center Drive, Building 31, 11A01, Bethesda,
MD 20892.
Contact Person: Amy Williams, NCI Office
of Advocacy Relations, National Cancer
Institute, NIH, 31 Center Drive Building 31,
Room 10A28, Bethesda, MD 20892, 240–781–
3360, williaam@mail.nih.gov.
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: September 09, 2019.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
4487
Time: 9:30 a.m. to 4:00 p.m.
Agenda: Welcome and Chairman’s
Remarks, NCI Updates, Legislative Update,
Budget Update, and Director’s Update.
Place: National Institutes of Health, 31
Center Drive, Building 31, 11A01, Bethesda,
MD 20892.
Contact Person: Amy Williams, NCI Office
of Advocacy Relations, National Cancer
Institute, NIH, 31 Center Drive, Building 31,
Room 10A28, Bethesda, MD 20892, 240–781–
3360, williaam@mail.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
inspected before being allowed on
campus. Visitors will be asked to show
one form of identification (for example,
a government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: NCRA:
https://deainfo.nci.nih.gov/advisory/
ncra/ncra.htm, where an agenda and
any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic
Assistance Program Nos. 93.392, Cancer
Construction; 93.393, Cancer Cause and
Prevention Research; 93.394, Cancer
Detection and Diagnosis Research;
93.395, Cancer Treatment Research;
93.396, Cancer Biology Research;
93.397, Cancer Centers Support; 93.398,
Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of
Health, HHS)
Dated: February 11, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02470 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
E:\FR\FM\15FEN1.SGM
15FEN1
Agencies
[Federal Register Volume 84, Number 32 (Friday, February 15, 2019)]
[Notices]
[Pages 4486-4487]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02472]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Institute Clinical Trials and Translational Research
Advisory Committee.
[[Page 4487]]
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting. The meeting will also be videocast and can be
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
Name of Committee: National Cancer Institute Clinical Trials and
Translational Research Advisory Committee.
Date: July 17, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: Strategic Discussion of NCI's Clinical and Translational
Research Programs.
Place: National Cancer Institute Shady Grove, East Wing, Seminar
Room 110, 9609 Medical Center Drive, Rockville, MD 20850.
Contact Person: Sheila A. Prindiville, MD, MPH Director,
Coordinating Center for Clinical Trials, National Institutes of
Health, National Cancer Institute, Coordinating Center for Clinical
Trials, 9609 Medical Center Drive, Room 6W136, Rockville, MD 20850,
240-276-6173 prindivs@mail.nih.gov.
Name of Committee: National Cancer Institute Clinical Trials and
Translational Research Advisory Committee.
Date: November 6, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: Strategic Discussion of NCI's Clinical and Translational
Research Programs.
Place: National Cancer Institute Shady Grove, East Wing,
Conference, Room TE406, 9609 Medical Center Drive, Rockville, MD
20850.
Contact Person: Sheila A. Prindiville, MD, MPH, Director,
Coordinating Center for Clinical Trials, National Institutes of
Health, National Cancer Institute, Coordinating Center for Clinical
Trials, 9609 Medical Center Drive, Room 6W136, Rockville, MD 20850,
240-276-6173, prindivs@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NCI Shady Grove has instituted
stringent procedures for entrance into the NCI Shady Grove building.
Visitors will be asked to show one form of identification (for
example, a government-issued photo ID, driver's license, or
passport) and to state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: https://deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 11, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-02472 Filed 2-14-19; 8:45 am]
BILLING CODE 4140-01-P